Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia resolves warning letter issues

Executive Summary

FDA is satisfied with Pharmacia's response to its April 17 warning letter relating to Caguas, Puerto Rico plant, company says (1"The Pink Sheet" May 20, p.7)...

You may also be interested in...



Pharmacia Is “Recidivist” On GMPs, FDA Says After Two Warnings In 5 Years

FDA considers two GMP warning letters issued to the same plant more than five years apart to be evidence that a company is "recidivist" on compliance issues, the agency told Pharmacia

Alembic Aims To Build On Booming US Business

With its predominantly solid-dose portfolio in the US producing strong growth, India’s Alembic Pharmaceuticals is increasingly securing FDA clearance to push into differentiated dosage forms.

Dermocosmetics Push Yields Results For Switzerland's Galenica

Launching skin-care products that blend "natural medicinal plants from the Swiss pharmacopoeia with the best Swiss skin science" helped to drive up Galenica's OTC sales in 2019 at a double-digit rate.
UsernamePublicRestriction

Register

PS040025

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel